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We studied effectiveness of the AS04-adjuvanted HPV-16/18 (AS04-HPV-16/18) vaccine against human papillomavirus (HPV)
oropharyngeal infections associated with the increase of head/neck cancers in western countries. All 38,631 resident
adolescents from 1994 to 1995 birth cohorts of 33 Finnish communities were invited in this community-randomized trial
(NCT00534638). During 2008–2009, 11,275 girls and 6,129 boys were enrolled in three arms of 11 communities each. In
Arm A, 90% of vaccinated girls/boys, and in Arm B, 90% of vaccinated girls received AS04-HPV-16/18 vaccine. Other Arm A/B
and all Arm C vaccinated participants received control vaccine. All Arm A participants and Arm B female participants were
blinded to vaccine allocation. Oropharyngeal samples were analyzed from 4,871 18.5-year-old females who attended follow-up
visit 3–6 years postvaccination. HPV DNA prevalence was determined by SPF-10 LiPA and Multiplex type-speciﬁc PCR. Total
vaccine effectiveness (VE) was deﬁned as relative reduction of oropharyngeal HPV prevalence in pooled Arms A/B HPV-
vaccinated females vs. all Arm C females. VE against oropharyngeal HPV-16/18, HPV-31/45 and HPV-31/33/45 infections were
82.4% (95% conﬁdence intervals [CI]: 47.3–94.1), 75.3% (95%CI: 12.7–93.0) and 69.9% (95% CI: 29.6–87.1), respectively.
In conclusion, the AS04-HPV-16/18 vaccine showed effectiveness against vaccine and nonvaccine HPV-types oropharyngeal
infections in adolescent females up to 6 years postvaccination.
Additional Supporting Information may be found in the online version of this article.
Key words: human papillomavirus, oral infection, oropharyngeal cancer, vaccine effectiveness
Abbreviations: Al: aluminum; AS04-HPV-16/18: AS04-adjuvanted HPV-16/18 vaccine; CI: conﬁdence interval; GCP: good clinical practice;
HBV: hepatitis B virus; HPV: human papillomavirus; hrHPV: high-risk human papillomaviruses; IARC: International Agency for Research on
Cancer; MPL: monophosphoryl lipid A; n (%): number (percentage) of subjects reporting an event; N: number of subjects with available results;
OPSCC: oropharyngeal squamous cell cancer; VE: vaccine effectiveness
Conﬂict of interest All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: ML
received grants from Merck & Co. Inc. and from the GSK group of companies through his employer, the University of Tampere. DA received
grants from the GSK group of companies through his employer, the Family Federation Finland for the conduct of HPV vaccination studies.
TE, KH, MH, TL and KN have no potential conﬂicts of interest to declare. SD, MS, DB and FS are employed by the GSK group of companies.
SD, DB and FS hold shares in the GSK group of companies. Cervarix and Engerix B are trademarks owned by or licensed to the GSK group of
companies.
Grant sponsor: GlaxoSmithKline Biologicals SA
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction
in any medium, provided the original work is properly cited.
DOI: 10.1002/ijc.32791
History: Received 18 Jul 2019; Accepted 29 Oct 2019; Online 17 Nov 2019
Correspondence to: Dan Bi, E-mail: dan.x.bi@gsk.com
International Journal of Cancer
IJC


















Oncogenic, high-risk human papillomaviruses (hrHPV) cause
worldwide 9% of cancers in females and 1% in males.1 More than
15 years ago, a retrospective case-series and a large nested case–
control study showed that infection with HPV-16 is associated
with a high risk of oropharyngeal squamous cell cancer
(OPSCC)2,3 that develops 10 or more years after acquisition of the
infection.3 Identiﬁcation of HPV DNA in oropharyngeal and ton-
sillar tumor tissues have conﬁrmed these observations.4,5 In 2009,
the International Agency for Research on Cancer (IARC) recog-
nized the causal role of HPV-16 in the etiology of cancers of the
oropharynx and tonsil.6 The HPV association is most true for
lymphoepithelial associatedOPSCC-subsites5 infected withHPV.
In western countries, the incidence of HPV-positive OPSCC
has increased very rapidly, virtually doubling in a decade since
the 1970s.7,8 Such trends have not been observed in HPV-negative
OPSCC. The former is clinically signiﬁcantly more favorable9 and
can be identiﬁed/monitored using HPV early antigen anti-
bodies.10 Thus, HPV testing is important but prospects for
screening of HPV-positive OPSCCs may not be optimal due to
the lack of deﬁned manageable precancerous lesions. Moreover,
in vaccinated populations with low background prevalence the
predictive values for any screening test11 will be demanding.
In the adolescent and young adult populations, the prevalence
of oral HPV infections varies widely from 0.4% to 10% mostly
depending on the method used for viral DNA detection.12–15
While HPV vaccination induces antibody levels at oral cavity that
correlate with circulating antibody levels,16,17 the efﬁcacy of pro-
phylactic HPV vaccines against oral infections has not been exten-
sively studied. Up to 88% reduction of oral hrHPV infections in
vaccine recipients as compared to nonvaccinated adolescents was
recently suggested18 but randomized trial data are scarce.12 Based
on a large community-randomized trial19 we now report second-
ary objective results on the total vaccine effectiveness (VE) of the
AS04-adjuvanted HPV-16/18 (AS04-HPV-16/18) vaccine against
oropharyngeal HPV infections in adolescent females in Finland.20
Materials and Methods
Community randomization
All the 33 randomized Finnish communities had more than
35,000 inhabitants.19 HPV-16/18 seroprevalence rates by com-
munity were estimated based on sera from the population-based
Finnish Maternity Cohort.19 Each study arm comprised 4 high
(>24%), 3 intermediate (24–20.5%) and 4 low (<20.5%) HPV-
16/18 seroprevalence communities. HPV seroprevalence is a
measure of the cumulative HPV incidence, and as such gives a
valid estimate of the background HPV exposure. This reduced
the coefﬁcient of variation across arms, and increased statistical
power.19
Ethics
The primary HPV-040 trial (NCT00534638, clinicaltrialgov.
com) and its amendment for the collection of the oral gargle
samples were approved by the ethical committee of the
Pirkanmaa hospital district in 2007 and 2011. The trial was
conducted in accordance with good clinical practice (GCP)
and all applicable regulatory requirements including the
Declaration of Helsinki. Participants aged <15 years provided
written informed assent; written informed consent was
obtained from the participants’ parents or legal representatives.
Written informed consent was obtained from study partici-
pants aged 15 years in line with local regulations.
Study procedures
In the 2008–2009 school year, invitation letters were sent to
the parents or legal guardians of all the 80,272 Finnish or
Swedish speaking 1992–1995 born adolescents residents in the
33 communities identiﬁed by the Finnish Population Informa-
tion System maintained by the Population Register Centre.
The letters included trial information, parental and adoles-
cents’ consent forms and a prepaid return envelope.
The vaccination (ﬁrst three study visits) took place at the
healthcare facilities of 250 municipal junior high schools of
the study site communities. In Arm A, 90% of vaccinated par-
ticipants received Cervarix (AS04-HPV-16/18; GSK) vaccine,
and 10% received Engerix B vaccine (hepatitis B virus [HBV]
vaccine; GSK).19 AS04 is an Adjuvant System containing
monophosphoryl lipid A (50 μg MPL; produced by GSK)
adsorbed on Aluminum salt (500 μg Al3+). In Arm B, 90%
of vaccinated females received the AS04-HPV-16/18 vaccine,
and 10% of vaccinated females and all vaccinated males
received the HBV vaccine. The 90 and 10% proportions were
receiver-blinded proportions to assess the herd effect. The
blinding was maintained for girls and boys in Arm A and for
girls in Arm B. In Arm C communities, all vaccinated partici-
pants received the HBV vaccine. Virtually all (99%) vaccinated
participants received all three vaccine doses.
Both vaccinated and nonvaccinated females of the 1994–1995
birth cohorts from the study site communities were invited to
attend follow-up visit at the age of 18.5 years during 2012–2014.
What’s new?
The incidence of oropharyngeal cancers due to human papillomavirus (HPV) infection is increasing in Western countries.
However, the efﬁcacy of HPV vaccines against oropharyngeal infection is not well documented. Based on a large community-
randomized trial in Finland, the authors report high effectiveness (82.4%) of Cervarix vaccine against oropharyngeal HPV-
16/18 infection and moderate effectiveness against non-vaccine types HPV-31/33/45 infection in female adolescents. The
protective effects were observed up to 6 years after vaccination. These results provide further evidence that HPV vaccination
holds the potential to reduce oral HPV infection, thereby offering protection against HPV-related head and neck cancers.
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Cervical and oropharyngeal samples for HPV DNA testing were
obtained on each visit. Setting the age for attending the follow-
up visit at 18.5 years was per protocol to allow a minimum of
3 years between vaccination and cervical sampling.19
During the follow-up visit, the attendees ﬁlled-in a ques-
tionnaire on living conditions, life-habits and sexual behavior.
At age 18.5 years, a cross-vaccination with either the HBV
vaccine or the AS04-HPV-16/18 vaccine was offered to the
attendees. Female attendees (139), who had moved between
Arm C and Arm A or B communities during the follow-up by
age 18.5 years were removed from the ﬁnal analyses.
Laboratory analyses
All samples were analyzed by PCR for HPV DNA. HPV typing
was performed by a broad-spectrum PCR SPF10-LiPA25 (Labo
Biomedical Products, Rijswik, the Netherlands) using HPV-
speciﬁc hybridization probes enabling detection of 14 oncogenic
HPV types (HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 66 and 68) and 11 nononcogenic HPV types (HPV-6,
11, 34, 40, 42, 43, 44, 53, 54, 70 and 74). To ensure maximum
sensitivity in the detection of HPV-16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 66, 68, 6 and 11, samples initially considered
to be SPF-10/DEIA positive for HPV were re-evaluated by the
multiplex type-speciﬁc PCR.20
Statistical analyses
The number of subjects invited to participate in the study and
the number of subjects enrolled was tabulated by gender, for
birth cohorts 1994, 1995 and overall.
The analysis of VE was done on female study participants
and was based on the total enrolled cohort which included all
study participants from all communities, including subjects
who only completed the behavioral questionnaire at 18.5 years
of age. For the analysis of a speciﬁc endpoint, only subjects
with measured endpoints were considered.
The statistical analysis of VE of the AS04-HPV-16/18 vac-
cine against oropharyngeal infection was done by comparing
the prevalence in females vaccinated with the AS04-HPV-
16/18 vaccine from pooled Arms A and B over the prevalence
in all females from Arm C for birth cohorts 1994–1995, for
the following HPV types: HPV-16, HPV-18, HPV-16/18,
HPV-6/11, HPV-31/45 and HPV-31/33/45.
The VE was computed as 1 minus the odd ratio of preva-
lence rates between the investigated arms and the control arm,
estimated using the Mantel–Haenszel test adjusted for cluster-
ing and stratiﬁed by the historical seroprevalence used in the
randomization (historical seroprevalence under 20.5%, between
20.5–24% and over 24%). The 95% conﬁdence interval (CI) on
VE was computed using the general inverse variance approach.
As a post hoc analysis, the VE of the AS04-HPV-16/18
vaccine against oropharyngeal infection for birth cohorts
1994–1995 was computed for the following HPV types: HPV-
31, HPV-33, HPV-35, HPV-45 and HPV-52. For this post
hoc analysis, only point estimated of the VE was provided due
to the low number of events. It was computed as 1 minus the
prevalence (Supporting Information Table S1) in females vac-
cinated with the AS04-HPV-16/18vaccine from pooled arms
A and B over the prevalence in all females from Arm C.
Data availability
Anonymized individual participant data and study documents
can be requested for further research from www.clinic
alstudydatarequest.com.
Results
Recruitment and follow-up visit
Recruitment to the trial was population-based and essentially
balanced across all three study arms (Table 1). Also, attendance
to the follow-up visit at the age of 18.5 years by vaccinated
female trial participants and nonvaccinated female residents of
the different trial arm communities was similar.
Vaccine effectiveness against oropharyngeal HPV infections
We found high to moderate VE against oropharyngeal hrHPV
infections. VE against vaccine HPV types 16/18 was high
(82.4%; 95% CI 47.3, 94.1), and indistinguishable between the
Table 1. Number (%) of invited, enrolled and followed females by
vaccination arm and birth cohort in 2008–2009* and 2012–2014
(follow-up visit)
Birth cohort
Arm 1994 1995 Total
A
Invited 3,063 2,846 5,909
Enrolled 1,964 (64.1) 1,660 (58.3) 3,624 (61.3)
Followed 831 775 1,606
B
Invited 3,572 3,408 6,980
Enrolled 2,059 (57.6) 1,913 (56.1) 3,972 (56.9)
Followed 813 773 1,586
C
Invited 3,040 3,027 6,067
Enrolled 1,890 (62.2) 1,789 (59.1) 3,679 (60.6)
Followed 846 833 1,679
All
Invited 9,675 9,281 18,956
Enrolled 5,913 (61.1) 5,362 (57.8) 11,275 (59.5)
Followed 2,490 2,381 4,871
Arm A: 90% of vaccinated females and males received the AS04-adjuvanted
HPV-16/18 (AS04-HPV-16/18) vaccine, 10% received the hepatitis B virus
(HBV) vaccine. Arm B: 90% of vaccinated females received the
AS04-HPV-16/18 vaccine, 10% of vaccinated females and 100% vaccinated
males received the HBV vaccine. Arm C: 100% of vaccinated females and
males received the HBV vaccine. The total enrolled cohort included all study
participants from all communities, including subjects who only completed
the behavioral questionnaire at 18.5 years of age. The followed females
included all subjects with human papillomavirus (HPV) DNA Polymerase
Chain Reaction result available for the oral gargle sample taken at the
follow-up visit and used in the computation of the total vaccine effective-
ness. *Q1/2010, for the 1995 birth cohort.
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two types (Table 2). VE against cross-protected HPV types
31/45 and 31/33/45 was 75.3% (95% CI: 12.7, 93.0) and 69.9%
(95% CI 29.6, 87.1), respectively.
No VE was found against other hrHPV types (Table 2).
VE estimate against the most notable low-risk HPV types
6/11 was low (25.8; 95% CI −21.7, 54.8).
Discussion
We found for the AS04-HPV-16/18 vaccine high VE against oro-
pharyngeal infections with the vaccine HPV types 16 and 18 and
a moderate VE against a prespeciﬁed combination of hrHPV
types 31/33/45 not included in the vaccine. These results are in
line with the reported, respectively high and moderate VEs of
the AS04-adjuvanted HPV-16/18 vaccine against cervical
HPV-16/18 and HPV-31/33/45 infections.20–23
We hereby disclose results of our trial’s secondary objective
that was to evaluate VE of the AS04-HPV-16/18 vaccine against
oropharyngeal infections in females of the 1994 and 1995 birth
cohorts at the age of 18.5 years. Other objectives will be described
in a separate publication and are available on the Clinical Trial
Register (www.clintrialsgov.com; NCT00534638). The analyses
related to the present objective are descriptive only.
For the targeted 1994–1995 birth cohorts, early vaccination
age of 12–14 years at the baseline of our population-based
community-randomized trial mimics national vaccination pro-
grams as does the female HPV vaccination coverage of approxi-
mately 50% in the HPV-vaccination arms. The early age at
vaccination was optimal for the vaccine-induced immune
response and to ensure the lowest possible proportion of base-
line positives. High attendance rates of both originally vacci-
nated female participants and unvaccinated female residents at
the age of 18.5 years retained the population-based nature of
our trial. This yielded robust VE estimates from the comparison
of HPV-16/18 vaccinated females in combined Arms A/B vs.
non-HPV-16/18 vaccinated females in Arm C.
There was a long lag of 4–6 years in the collection of oral
gargle samples postvaccination, while the oropharyngeal base-
line HPV infection status in the study participants prior to vac-
cination was unknown. Identiﬁcation of hrHPV types by highly
sensitive PCR in the oral gargle is, however, the most compre-
hensive means for the identiﬁcation of oropharyngeal HPV
infections.24 Whether the identiﬁcation of hrHPV type(s) in
these cross-sectional samples taken at the age of 18.5 years rep-
resents persistent infection can therefore not be judged, and
must be considered as a limitation of the study. On the other
hand, while 6 months and 12 months persistent positivity for
the same HPV type has been used to deﬁne persistent cervical
or other anogenital infections, very little is known about the
duration of oropharyngeal infections. In the future, vaccine efﬁ-
cacy against oropharyngeal persistent hrHPV infection will be
documented in an ongoing 10-year follow-up study with serial
oral gargle sampling.
In conclusion, high VE against oropharyngeal infections
with vaccine HPV types 16/18 and moderate VE against infec-
tions with nonvaccine HPV types 31/33/45 was observed in
young adult females up to 6 years postvaccination with the
AS04-HPV-16/18 vaccine. Our study provides further
evidence that HPV vaccination could probably reduce oral
HPV infections which may translate into protection against
HPV-related head and neck cancers.
Acknowledgements
The authors thank the study participants and their families for their par-
ticipation in our study. The devoted, high-quality work of the 85 study
nurses responsible for the trial recruitment and follow-up has been invalu-
able. The authors acknowledge the principal investigators for their contri-
bution to the study and the contributors at the University of Tampere.
The authors would also like to acknowledge the contribution of Pia
Brandt from Smerud Medical Research and Katri Ventola-Seppälä from
Medﬁles. Thank you to Heidi Ilomäki, Ulpu Andersson, Nina Pellosniemi,
Aila Rajaheimo, Liisa Heikkilä and Markku Pulkkinen (retired) from GSK
Finland for management and coordination of the study activities. The
authors also wish to thank the steering committee of the HPV-040 trial,
amongst others, Allan Donner, Eduardo Franco, Pauli Leinikki, and
Margaret Stanley for their scientiﬁc advice and support throughout the
study. The authors thank Business & Decision Life Sciences platform for
editorial assistance and publication coordination, on behalf of GSK. Bruno
Baudoux coordinated manuscript development and editorial support. This
work was sponsored by GlaxoSmithKline Biologicals SA who was involved
in all stages of study conduct, data analysis, and development of the
related publications.
Table 2. Total vaccine effectiveness against oropharyngeal infection
with HPV in AS04-HPV-16/18 vaccinated females (pooled Arms A/B)
vs. non-AS04-HPV-16/18 vaccinated females (Arm C) for birth cohorts
1994–1995 vaccinated in 2007–2009 and attending follow-up visits










Arms A/B vs. Arm C
VE % (95% CI)
HPV-6/11 41 (1.3) 29 (1.7) 25.8 (−21.7, 54.8)
HPV-16 6 (0.2) 19 (1.1) 81.3 (25.8, 95.3)
HPV-18 4 (0.1) 10 (0.6) 78.9 (32.3, 93.4)
HPV-16/18 9 (0.3) 27 (1.6) 82.4 (47.3, 94.1)
HPV-31 2 (0.1) 8 (0.5) 86.81
HPV-33 6 (0.2) 9 (0.5) 64.91
HPV-35 3 (0.1) 3 (0.2) 47.41
HPV-45 1 (0.0) 1 (0.1) 47.41
HPV-52 14 (0.4) 12 (0.7) 38.61
HPV-31/45 3 (0.1) 9 (0.5) 75.3 (12.7, 93.0)
HPV-31/33/45 9 (0.3) 16 (1.0) 69.9 (29.6, 87.1)
Arm A: 90% of vaccinated females and males received the AS04-adjuvanted
HPV-16/18 (AS04-HPV-16/18) vaccine, 10% received the hepatitis B-virus
(HBV) vaccine. Arm B: 90% of vaccinated females received the
AS04-HPV-16/18 vaccine, 10% of vaccinated females and 100% vaccinated
males received the HBV vaccine. Arm C: 100% of vaccinated females and
males received the HBV vaccine.
1Only point estimated of VE was provided for this post hoc analysis due
to the low number of events.
Abbreviations: CI, confidence interval; HPV, human papillomavirus; N,
number of subjects with available results; n (%), number (percentage) of
subjects reporting an event; VE, total vaccine effectiveness.
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